Literature DB >> 2007514

[Cartilage-damaging effect of quinolones].

R Stahlmann1.   

Abstract

The cartilage damaging effect of quinolones on juvenile experimental animals represents an unusual effect which is unknown, in this form, for other classes of substances. Since the damage is manifested at quite low doses the manufacturers and regulatory agencies have taken the consequence of declaring these preparations counter-indicated for children and adolescents up to the end of the growing period. Motor disturbances were observed only rarely, and only in individual cases, seen after therapeutic use of these drugs for the treatment of bacterial infections. In spite of long-term and sometimes high dose treatment with nalidixic acid during the 1960s and 1970s (the arthropathogenic effect on dogs was first described in 1977) no joint alterations could be demonstrated clinically or by x-ray. From this conclusion can be drawn that the effects seen in animal experiments under therapeutic conditions do not occur with the same intensity in humans. But, since many questions concerning this unusual toxic potential are still unanswered, quinolones continue to be counter-indicated for patients who are in the growing phase. Further experimental data and clinical observations are necessary to exclude with certainty the possible danger of joint damage to young patients. Even today it is still unclear whether the generally favourable clinical observations made with nalidixic acid also hold true for the other quinolones and whether differences in the possible risks exist. It will only become possible to define, with the necessary amount of certainty, indications for the use of quinolones in pediatrics when further information is available.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007514     DOI: 10.1007/bf01644734

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  22 in total

1.  Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations.

Authors:  R Stahlmann; H J Merker; N Hinz; I Chahoud; J Webb; W Heger; D Neubert
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

2.  Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids.

Authors:  A Gough; N J Barsoum; L Mitchell; E J McGuire; F A de la Iglesia
Journal:  Toxicol Appl Pharmacol       Date:  1979-10       Impact factor: 4.219

3.  Ciprofloxacin and tenosynovitis.

Authors:  S R McEwan; P G Davey
Journal:  Lancet       Date:  1988-10-15       Impact factor: 79.321

4.  Use of enoxacin in a patient with cystic fibrosis.

Authors:  M G Miller; A T Ghoneim; J M Littlewood
Journal:  Lancet       Date:  1985-03-16       Impact factor: 79.321

5.  Arthropathy in a patient with cystic fibrosis taking ciprofloxacin.

Authors:  M Alfaham; M E Holt; M C Goodchild
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-19

6.  Norfloxacin-induced rheumatic disease.

Authors:  R R Bailey; J A Kirk; B A Peddie
Journal:  N Z Med J       Date:  1983-07-27

Review 7.  Use of quinolones in pediatric patients.

Authors:  D Adam
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

8.  Pharmacokinetics of ciprofloxacin. 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C]ciprofloxacin in albino rats.

Authors:  H M Siefert; D Maruhn; H Scholl
Journal:  Arzneimittelforschung       Date:  1986-10

9.  Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity.

Authors:  U B Schaad; J Wedgwood-Krucko
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

10.  Effect of ofloxacin on the uptake of [3H]thymidine by articular cartilage cells in the rat.

Authors:  M Kato; T Onodera
Journal:  Toxicol Lett       Date:  1988-11       Impact factor: 4.372

View more
  5 in total

1.  Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro.

Authors:  M Menschik; J Neumüller; C W Steiner; L Erlacher; M Köller; R Ullrich; W Graninger; W B Graninger
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 2.  Quinolones in children. Are concerns over arthropathy justified?

Authors:  R Stahlmann; C Förster; D Van Sickle
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 3.  Safety and tolerability of fluoroquinolones.

Authors:  S R Norrby; P S Lietman
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  Chondrotoxicity of quinolones in vivo and in vitro.

Authors:  H Hildebrand; G Kempka; G Schlüter; M Schmidt
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

Review 5.  Safety and efficacy of ciprofloxacin in paediatric patients--review.

Authors:  R Kubin
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.